The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease

Update Item Information
Identifier 20230314_nanos_posters_306
Title The Role of Teprotumumab in the Treatment of Diplopia Due to Thyroid Eye Disease
Creator Shwetha Mudalegundi; Peng Huang; Amanda Henderson; Andrew Carey
Affiliation (SM) (PH) (AH) Wilmer Eye Institute, Johns Hopkins; (AC) Wilmer Eye Institute, Johns Hopkins University School of Medicine
Subject Graves' Disease; Adult Strabismus; Diplopia; Miscellaneous
Description Thyroid Eye Disease (TED) is a vision threatening condition caused by inflammatory damage to the periocular tissue. Teprotumumab is an IGF-1R antibody that was FDA approved for the management of TED in 2020, although much is yet to be elucidated regarding its effects on diplopia outcomes among TED patients. Diplopia is a significant and life altering effect of TED. Prior studies have reported teprotumumab's effect on double vision subjectively using the Gorman diplopia score. However, there is a gap in the literature addressing the effect of teprotumumab treatment on objective ocular alignment measures, and this is what we aim to address.
Date 2023-03-14
Language eng
Format application/pdf
Type Text
Source 2023 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2023: Poster Session II: Neuro-Ophthalmic Practice
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6xarmk4
Setname ehsl_novel_nam
ID 2335511
Reference URL https://collections.lib.utah.edu/ark:/87278/s6xarmk4
Back to Search Results